Patent details

Basic Information

Publication number:

EP3719020

PCT Application Number:

CN2018118864

Type:

European Patent Granted for LU

Legal Status:

Lapsed

Application number:

EP188847446

PCT Publication Number:

WO2019105479

First applicant's nationality:

Translation Language:

EPO Publication Language:

English

English Title of Invention:

CRYSTAL FORM OF BETA-LACTAMASE INHIBITOR AND PREPARATION METHOD THEREFOR

French Title of Invention:

FORME CRISTALLINE D'UN INHIBITEUR DE BETA-LACTAMASE ET SON PROCÉDÉ DE PRÉPARATION

German Title of Invention:

KRISTALLINE FORM VON BETA-LACTAMASE-INHIBITOR UND HERSTELLUNGSVERFAHREN DAFÜR

SPC Number:

Dates

Filing date:

03/12/2018

Grant date:

21/09/2022

EP Publication Date:

07/10/2020

PCT Publication Date:

06/06/2019

Claims Translation Received Date:

Translations Received Date (B1 EP Publication):

Translations Received Date (B2 EP Publication):

Translations Received Date (B3 EP Publication):

Publication date:

21/09/2022

EP B1 Publication Date:

21/09/2022

EP B2 Publication Date:

EP B3 Publication Date:

Lapsed date:

03/12/2022

Expiration date:

03/12/2038

Renunciation date:

Revocation date:

Annulment date:

Owner

From:

14/09/2022

 

 

Name:

QILU PHARMACEUTICAL CO., LTD.

Address:

No. 317, Xinluo Street, High Technical Zone Jinan Shandong 250100, China (CN)

Inventor

1

Name:

LI, Weidong

Address:

China (CN)

2

Name:

LI, Cheng

Address:

China (CN)

3

Name:

DING, Charles Z.

Address:

China (CN)

4

Name:

HUANG, Zhigang

Address:

China (CN)

Priority

Priority Number:

201711251386

Priority Date:

01/12/2017

Priority Country:

China (CN)

Classification

IPC classification:

C07D 471/08; A61K 31/439; A61P 31/04;

Publication

European Patent Bulletin

Issue number:

202238

Publication date:

21/09/2022

Description:

Grant (B1)

Annual Fees

Annual Fee Due Date:

Annual Fee Number:

Expected Payer:

Last Annual Fee Payment Date:

Last Annual Fee Paid Number:

Payer:

Filing date	Document type	Number of pages